RightFit Trial Directory

Leukemia clinical trials in New York, NY

59 recruiting leukemia studies with a site in New York, NY.

All trials in New York, NY · All Leukemia trials

RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor: Alliance for Clinical Trials in Oncology

Buffalo, NY · Lake Success, NY · Manhasset, NY · +452 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Albany, NY · Buffalo, NY · New Hyde Park, NY · +112 more sites

RecruitingPhase 2NCT05554393

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Buffalo, NY · Commack, NY · New York, NY · +172 more sites

RecruitingPhase 1NCT06846606

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Sponsor: Auron Therapeutics, Inc.

Buffalo, NY · New York, NY · +7 more sites

RecruitingPhase 1NCT04301076

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Sponsor: National Cancer Institute (NCI)

Commack, NY · Harrison, NY · Mineola, NY · +16 more sites

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Buffalo, NY · Commack, NY · Lake Success, NY · +222 more sites

RecruitingPhase 1 / Phase 2NCT06137118

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Sponsor: AstraZeneca

New York, NY · +11 more sites

RecruitingPhase 2NCT06672146

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Buffalo, NY · Commack, NY · Harrison, NY · +132 more sites

RecruitingPhase 3NCT07007312

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Sponsor: Kura Oncology, Inc.

Buffalo, NY · New York, NY · +41 more sites

RecruitingPhase 1 / Phase 2NCT04065399

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Sponsor: Syndax Pharmaceuticals

New York, NY · +20 more sites

RecruitingPhase not listedNCT07143669

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Sponsor: Blueprint Medicines Corporation

New York, NY · +24 more sites

RecruitingPhase 2NCT07605416

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

Sponsor: National Cancer Institute (NCI)

Buffalo, NY · Commack, NY · Harrison, NY · +7 more sites

RecruitingPhase 1NCT05091424

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Sponsor: Hoffmann-La Roche

New York, NY · +4 more sites

RecruitingPhase 2NCT07061951

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Sponsor: National Cancer Institute (NCI)

New York, NY · +8 more sites

RecruitingPhase 2NCT05592015

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Sponsor: Jonathan Brammer

New York, NY · +2 more sites

RecruitingPhase 1NCT03802695

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Sponsor: Orca Biosystems, Inc.

New York, NY · +11 more sites

RecruitingPhase 2NCT06514794

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Sponsor: Allotera Therapeutics

New York, NY · +15 more sites

RecruitingPhase 3NCT07277231

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Sponsor: BeOne Medicines

New York, NY · +21 more sites

RecruitingPhase 1 / Phase 2NCT04925479

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Sponsor: Novartis Pharmaceuticals

New York, NY · +7 more sites

RecruitingPhase 3NCT06852222

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Sponsor: Janssen Research & Development, LLC

Buffalo, NY · New York, NY · +56 more sites

RecruitingPhase 1NCT07661095

A Study of CRD3874-SI in People With Leukemia

Sponsor: Memorial Sloan Kettering Cancer Center

Commack, NY · Harrison, NY · New York, NY · +4 more sites

RecruitingPhase 3NCT04293562

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Sponsor: Children's Oncology Group

Albany, NY · Brooklyn, NY · Buffalo, NY · +183 more sites

RecruitingPhase 2NCT06824168

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Sponsor: Daiichi Sankyo

Buffalo, NY · New York, NY · Valhalla, NY · +12 more sites

RecruitingPhase 2NCT04996875

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Sponsor: Cogent Biosciences, Inc.

New York, NY · +13 more sites

RecruitingPhase 1 / Phase 2NCT03104491

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Sponsor: Leland Metheny

New York, NY · +6 more sites

RecruitingPhase 1NCT05010005

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Sponsor: Memorial Sloan Kettering Cancer Center

Commack, NY · Harrison, NY · New York, NY · +6 more sites

RecruitingPhase 1NCT03666000

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Sponsor: Imugene Limited

New York, NY · +9 more sites

RecruitingPhase 2 / Phase 3NCT03013998

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Sponsor: Beat AML, LLC

New York, NY · Rochester, NY · +29 more sites

RecruitingPhase 1 / Phase 2NCT04726241

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Sponsor: PedAL BCU, LLC

Albany, NY · Brooklyn, NY · Mineola, NY · +161 more sites

RecruitingPhase 1NCT06247787

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Sponsor: Children's Oncology Group

New York, NY · +18 more sites

RecruitingPhase 1NCT06001788

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Sponsor: Kura Oncology, Inc.

Buffalo, NY · Lake Success, NY · New York, NY · +35 more sites

RecruitingPhase 4NCT07486713

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Sponsor: Rigel Pharmaceuticals

New York, NY · +1 more sites

RecruitingPhase 1 / Phase 2NCT07155226

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Sponsor: AstraZeneca

New York, NY · +5 more sites

RecruitingPhase 1NCT05131022

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Sponsor: Nurix Therapeutics, Inc.

Ithaca, NY · New York, NY · +16 more sites

RecruitingPhase 1 / Phase 2NCT07356154

A Study of Revumenib and Mezigdomide in People With Leukemia

Sponsor: Memorial Sloan Kettering Cancer Center

Commack, NY · Harrison, NY · New York, NY · +7 more sites

RecruitingPhase 1NCT07011004

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

Sponsor: Memorial Sloan Kettering Cancer Center

Commack, NY · Harrison, NY · New York, NY · +4 more sites

RecruitingPhase 1NCT05768932

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Sponsor: SillaJen, Inc.

New York, NY · The Bronx, NY · +8 more sites

RecruitingPhase 1 / Phase 2NCT05848687

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Sponsor: Tanja Andrea Gruber

New York, NY · +16 more sites

RecruitingPhase not listedNCT05978141

A Registry for People With T-cell Lymphoma

Sponsor: Memorial Sloan Kettering Cancer Center

Commack, NY · Harrison, NY · New York, NY · +23 more sites

RecruitingPhase 2NCT05996185

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Sponsor: Yale University

New York, NY · +1 more sites

RecruitingPhase not listedNCT06297161

A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).

Sponsor: Pfizer

New York, NY

RecruitingPhase 3NCT06428019

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Sponsor: AbbVie

New York, NY · +31 more sites

RecruitingPhase 1 / Phase 2NCT04988555

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sponsor: Sumitomo Pharma America, Inc.

Buffalo, NY · New York, NY · +30 more sites

RecruitingPhase 2NCT07218510

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Sponsor: City of Hope Medical Center

New York, NY · +6 more sites

RecruitingPhase 2NCT06698003

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

Sponsor: Memorial Sloan Kettering Cancer Center

Commack, NY · Harrison, NY · New York, NY · +4 more sites

RecruitingPhase 4NCT06876649

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Sponsor: Eli Lilly and Company

Ithaca, NY · Lake Success, NY · New York, NY · +17 more sites

RecruitingPhase 2NCT06773208

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

Sponsor: Memorial Sloan Kettering Cancer Center

Commack, NY · Harrison, NY · New York, NY · +4 more sites

RecruitingEarly Phase 1NCT04512716

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Sponsor: Memorial Sloan Kettering Cancer Center

Commack, NY · Harrison, NY · New York, NY · +4 more sites

RecruitingPhase 1NCT04872478

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

Sponsor: Meryx, Inc.

New York, NY · +2 more sites

RecruitingPhase 1NCT06366789

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

Sponsor: Lomond Therapeutics Holdings, Inc.

New York, NY · +11 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.